Synaptiq Therapeutics Launches with Acquisition of Clinical-Stage SYN-001 Program

A new company has been formed to advance SYN-001, an FDA-designated orphan/rare pediatric disease therapeutic candidate acquired from Nobias Therapeutics, with a planned Phase IIb program. The study is intended to further evaluate SYN-001 for treating neuropsychiatric symptoms associated with 22q11.2 Deletion Syndrome. The update is largely developmental with limited immediate financial datapoints, suggesting modest near-term stock/sector impact.

Analysis

A new company has been formed to advance SYN-001, an FDA-designated orphan/rare pediatric disease therapeutic candidate acquired from Nobias Therapeutics, with a planned Phase IIb program. The study is intended to further evaluate SYN-001 for treating neuropsychiatric symptoms associated with 22q11.2 Deletion Syndrome. The update is largely developmental with limited immediate financial datapoints, suggesting modest near-term stock/sector impact.